Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2025-02-10 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 自愿披露关于注射用BAT1006联合曲妥珠单抗及化疗治疗乳腺癌获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by 百奥泰生物制药股份有限公司 regarding the approval of a clinical trial application for a drug (BAT1006) by the National Medical Products Administration (国家药品监督管理局). It contains no financial data, no financial statements, no management discussion of financial results, nor any regulatory certifications or officer attestations. The document is an announcement of a regulatory approval related to clinical trials, which is a regulatory update rather than a financial report or management report. It is not a report publication announcement since it does not mention any report being attached or published. It is not related to any shareholder meeting, capital changes, or legal proceedings. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-02-10 Chinese
百奥泰 关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 first extraordinary general meeting of shareholders (临时股东大会) for 百奥泰生物制药股份有限公司. It details the meeting date, voting methods, agenda items, registration procedures, and proxy authorization form. There is no financial data, earnings, or report content. It is an announcement of a shareholder meeting, not a report or results announcement. This fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-02-10 Chinese
百奥泰 关于司库奇尤单抗注射液（BAT2306）上市许可申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 百奥泰生物制药股份有限公司 regarding the acceptance of the drug marketing authorization application for their product BAT2306 by the Chinese National Medical Products Administration (NMPA). It includes details about the drug, regulatory approval status, and risk disclosures. The document is short (1058 characters) and serves as an official notice of regulatory acceptance rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed regulatory filings beyond the announcement itself. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-02-07 Chinese
百奥泰生物制药股份有限公司简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding of a significant shareholder (information disclosure obligor) in 百奥泰生物制药股份有限公司, including the reduction of shareholding from above 5% to exactly 5% due to block trades. The document references relevant Chinese securities laws and regulations governing disclosure of equity changes. It includes detailed information about the shareholder, the shareholding before and after the change, the method of change (block trade), and confirms no other share transactions in the past six months. This matches the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds (in this case, crossing the 5% threshold). The document is not an announcement of a report publication, nor is it a full annual or interim report, nor a regulatory filing of another type. Therefore, the correct classification is MRQ with high confidence.
2025-02-05 Chinese
百奥泰 关于持股5%以上股东权益下降至5%暨减持计划期限届满的减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the reduction of shareholding by a shareholder whose stake fell below 5%. It details the shareholding changes, reduction plan implementation, and related disclosures. The content focuses on shareholding changes by a major shareholder and the completion of a share reduction plan. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report itself but an official announcement of shareholding changes and reduction results. This fits the definition of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2025-02-05 Chinese
百奥泰 第二届监事会第十七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 17th meeting of the second Supervisory Board of 百奥泰生物制药股份有限公司. It details the approval of related-party transactions and confirms compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial data but rather reports on board-level decisions and approvals. It is not an annual report, audit report, or earnings release. It is also not a regulatory filing or report publication announcement since it contains substantive meeting resolution content. The content fits best under Board/Management Information (MANG) as it relates to supervisory board meeting decisions and approvals.
2025-01-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.